MX2014009078A - Tratamiento de trastornos del ritmo circadiano. - Google Patents

Tratamiento de trastornos del ritmo circadiano.

Info

Publication number
MX2014009078A
MX2014009078A MX2014009078A MX2014009078A MX2014009078A MX 2014009078 A MX2014009078 A MX 2014009078A MX 2014009078 A MX2014009078 A MX 2014009078A MX 2014009078 A MX2014009078 A MX 2014009078A MX 2014009078 A MX2014009078 A MX 2014009078A
Authority
MX
Mexico
Prior art keywords
treatment
circadian rhythm
rhythm disorders
patients
circadian
Prior art date
Application number
MX2014009078A
Other languages
English (en)
Inventor
Marlene Michelle Dressman
Louis William Licamele
Mihael H Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47679075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014009078(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of MX2014009078A publication Critical patent/MX2014009078A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2864—Sleep disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)

Abstract

Las modalidades de la invención se refieren al uso de un agonista de melatonina en el tratamiento de ritmos circadianos de curso libre en los pacientes, incluidos pacientes con deficiencia de percepción de la luz, por ejemplo, pacientes ciegos, y a métodos para medir el ritmo circadiano.
MX2014009078A 2012-01-26 2013-01-25 Tratamiento de trastornos del ritmo circadiano. MX2014009078A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261590974P 2012-01-26 2012-01-26
US201261640067P 2012-04-30 2012-04-30
US201261650455P 2012-05-22 2012-05-22
US201261650458P 2012-05-22 2012-05-22
US201261714149P 2012-10-15 2012-10-15
US201261738987P 2012-12-18 2012-12-18
US201261738985P 2012-12-18 2012-12-18
US201361755896P 2013-01-23 2013-01-23
PCT/US2013/023315 WO2013112951A2 (en) 2012-01-26 2013-01-25 Treatment of circadian rhythm disorders

Publications (1)

Publication Number Publication Date
MX2014009078A true MX2014009078A (es) 2016-01-25

Family

ID=47679075

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2014009079A MX367184B (es) 2012-01-26 2013-01-25 Uso de un agonista de melatonina en el tratamiento de ritmos circadianos de curso libre.
MX2014009078A MX2014009078A (es) 2012-01-26 2013-01-25 Tratamiento de trastornos del ritmo circadiano.
MX2019012197A MX2019012197A (es) 2012-01-26 2014-07-25 Tratamiento de trastornos del ritmo circadiano.
MX2020007448A MX2020007448A (es) 2012-01-26 2014-07-25 Tratamiento de trastornos del ritmo circadiano.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014009079A MX367184B (es) 2012-01-26 2013-01-25 Uso de un agonista de melatonina en el tratamiento de ritmos circadianos de curso libre.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2019012197A MX2019012197A (es) 2012-01-26 2014-07-25 Tratamiento de trastornos del ritmo circadiano.
MX2020007448A MX2020007448A (es) 2012-01-26 2014-07-25 Tratamiento de trastornos del ritmo circadiano.

Country Status (21)

Country Link
US (21) US8785492B2 (es)
EP (4) EP3620794A1 (es)
JP (10) JP2015509106A (es)
KR (10) KR102171965B1 (es)
CN (4) CN104519877A (es)
AU (9) AU2013211880A1 (es)
BR (2) BR112014018433A8 (es)
CA (4) CA3159064A1 (es)
CL (2) CL2014001992A1 (es)
CO (2) CO7131366A2 (es)
DK (1) DK2806863T3 (es)
ES (2) ES2646197T3 (es)
HR (1) HRP20171600T1 (es)
HU (1) HUE034876T2 (es)
IL (4) IL233714A0 (es)
IN (2) IN2014DN07132A (es)
MX (4) MX367184B (es)
PT (1) PT2806863T (es)
RU (2) RU2631602C2 (es)
SI (1) SI2806863T1 (es)
WO (2) WO2013112949A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2028937E (pt) * 2006-05-22 2015-04-09 Vanda Pharmaceuticals Inc Tratamento por agonista de melatonina
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
ES2646197T3 (es) 2012-01-26 2017-12-12 Vanda Pharmaceuticals Inc. Tratamiento de trastornos del ritmo circadiano
CN104583178A (zh) * 2012-05-18 2015-04-29 万达制药公司 (1r-反)-n-[[2-(2，3-二氢-4-苯并呋喃基)环丙基]甲基]丙酰胺代谢物
WO2014100292A1 (en) * 2012-12-18 2014-06-26 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
WO2015117048A1 (en) * 2014-01-31 2015-08-06 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CN106604726A (zh) 2014-09-02 2017-04-26 万达制药公司 用于治疗史密斯‑马吉利综合征的他司美琼
US10076286B1 (en) * 2014-10-21 2018-09-18 Verily Life Sciences Llc Methods and devices for circadian rhythm monitoring
WO2016109359A1 (en) * 2014-12-29 2016-07-07 Auspex Pharmaceuticals, Inc. Cyclopropyl dihydrobenzofuran modulators of melatonin receptors
US11013713B2 (en) * 2015-12-15 2021-05-25 Vanda Pharmaceuticals Inc. Method of treatment
TW201726617A (zh) 2016-01-06 2017-08-01 奧斯佩生物製藥公司 Ｓｉｒｔ１受體的四氫咔唑抑制劑
KR20190008265A (ko) 2016-05-06 2019-01-23 피지션즈 씰, 엘엘씨 발레리안 조성물 및 관련 방법
WO2018033546A1 (en) * 2016-08-18 2018-02-22 Koninklijke Philips N.V. Blood-pressure management
ES2965488T3 (es) * 2017-08-02 2024-04-15 Vanda Pharmaceuticals Inc Uso de tasimelteón para el tratamiento de trastornos afectivos en pacientes mayoritariamente negroafricanos
MX2020009159A (es) * 2018-03-04 2020-12-11 Vanda Pharmaceuticals Inc Tratamiento de trastornos con tasimelteon.
US11346169B2 (en) 2018-07-23 2022-05-31 Kobold Corporation Sleeve valves, shifting tools and methods for wellbore completion operations therewith
CN108828098B (zh) * 2018-07-24 2020-04-21 山东农业大学 一种高效液相色谱-质谱法测定棉花中褪黑素的方法
WO2020056117A1 (en) * 2018-09-12 2020-03-19 Vanda Pharmaceuticals Inc.. Improving sleep or post-sleep performance
KR102260252B1 (ko) * 2018-10-24 2021-06-03 주식회사 인코스팜 피부 세포를 통한 일주기 리듬 분석 방법, 일주기 리듬 장애를 정상화하는 방법 및 일주기 리듬 정보를 이용한 정보제공 시스템
CN109522688B (zh) * 2018-10-27 2023-10-13 平安医疗健康管理股份有限公司 基于数据处理的肾功能衰竭资质认证方法、设备及服务器
EP3671757A1 (en) * 2018-12-18 2020-06-24 Koninklijke Philips N.V. System and method for determining a level of alertness
CN114641284A (zh) * 2019-06-29 2022-06-17 万带兰制药公司 他司美琼在治疗睡眠异常中的应用
NZ789270A (en) * 2019-12-13 2024-07-05 Vanda Pharmaceuticals Inc Liquid tasimelteon formulations and methods of use thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50699A0 (en) 1975-10-28 1976-12-31 Ici America Inc Triazole derivatives
EP0126630B1 (en) 1983-05-18 1987-09-16 Monash University The use of melatonin for the manufacture of a medicament
IL79264A0 (en) 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US4997845A (en) 1987-02-02 1991-03-05 Eli Lilly And Company β-alkylmelatonins as ovulation inhibitors
US5093352A (en) 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
US5151446A (en) 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US6638963B1 (en) * 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
US5242941A (en) 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
IT1251544B (it) 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
US6180657B1 (en) 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
GB9416884D0 (en) 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
SK284521B6 (sk) 1995-02-01 2005-05-05 Neurim Pharmaceuticals (1991) Ltd. Použitie melatonínu na prípravu farmaceutického prostriedku
IL129999A (en) 1996-12-10 2004-06-20 Bristol Myers Squibb Co Melatonergic agents which are benzodioxole, benzopuran, dihydrobenzopuran and benzodioxane
US5776969A (en) 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
AUPO588297A0 (en) 1997-03-26 1997-04-24 Luminis Pty Limited Mediation in melatonin production
JP3055884B2 (ja) 1997-08-07 2000-06-26 花野商事株式会社 引きクランプ装置
AU4060599A (en) 1998-06-09 1999-12-30 Takeda Chemical Industries Ltd. Pharmaceutical composition for treating or preventing sleep disorders
US6562858B2 (en) 1999-05-17 2003-05-13 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating depression
US6211225B1 (en) 1999-06-30 2001-04-03 Bristol-Meyers Squibb Heterocyclic aminopyrrolidine derivatives as melatonergic agents
CN101912367A (zh) 2001-10-30 2010-12-15 诺瓦提斯公司 伊潘立酮和星状聚合物的贮库制剂
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
JP2005080603A (ja) 2003-09-10 2005-03-31 Kumamoto Technology & Industry Foundation 生体リズム障害の度合の判断方法
US20050137247A1 (en) 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
US20050164987A1 (en) 2003-12-24 2005-07-28 Barberich Timothy J. Melatonin combination therapy for improving sleep quality
GB0400031D0 (en) * 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
KR101187461B1 (ko) 2005-07-29 2012-10-02 반다 파마슈티칼즈, 인코퍼레이티드. 각성을 향상시키는 방법
US7754902B2 (en) 2006-05-18 2010-07-13 Vanda Pharmaceuticals, Inc. Ruthenium(II) catalysts for use in stereoselective cyclopropanations
PT2028937E (pt) * 2006-05-22 2015-04-09 Vanda Pharmaceuticals Inc Tratamento por agonista de melatonina
MX2008014840A (es) 2006-05-22 2008-12-05 Vanda Pharmaceuticals Inc Tratamiento de trastornos depresivos.
WO2008011150A1 (en) 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
WO2008011120A2 (en) 2006-07-21 2008-01-24 The Regents Of The University Of California Human endogenous retrovirus polypeptide compositions and methods of use thereof
WO2008070795A2 (en) 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
CN101678025A (zh) 2007-04-11 2010-03-24 生物马林药物股份有限公司 四氢生物蝶呤组合物及其测量方法
WO2009036257A1 (en) 2007-09-13 2009-03-19 Vanda Pharmaceuticals, Inc. Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype
WO2009084023A2 (en) 2007-10-19 2009-07-09 Glenmark Generics Limited Amorphous ramelteon and process for the preparation thereof
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
JP5558016B2 (ja) 2009-03-17 2014-07-23 株式会社 資生堂 概日リズム調整剤
MX2011010525A (es) * 2009-04-07 2012-04-02 Duocort Pharma Ab Terapia mejorada con glucocorticoides.
US20120136050A1 (en) 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
ES2646197T3 (es) 2012-01-26 2017-12-12 Vanda Pharmaceuticals Inc. Tratamiento de trastornos del ritmo circadiano
WO2014100292A1 (en) 2012-12-18 2014-06-26 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
EP3470405A1 (en) 2014-02-12 2019-04-17 Vanda Pharmaceuticals Inc. Highly purified pharmaceutical grade tasimelteon

Also Published As

Publication number Publication date
US11285129B2 (en) 2022-03-29
US11918556B2 (en) 2024-03-05
CA2861111A1 (en) 2013-08-01
PT2806863T (pt) 2017-11-09
KR20170058463A (ko) 2017-05-26
WO2013112951A3 (en) 2014-12-31
US10610510B2 (en) 2020-04-07
WO2013112949A2 (en) 2013-08-01
USRE46604E1 (en) 2017-11-14
IL233715A0 (en) 2014-09-30
JP2015508157A (ja) 2015-03-16
AU2021204784A1 (en) 2021-08-05
US10449176B2 (en) 2019-10-22
US11633377B2 (en) 2023-04-25
JP2019038822A (ja) 2019-03-14
CA2861108A1 (en) 2013-08-01
US20240197671A1 (en) 2024-06-20
US20170100366A1 (en) 2017-04-13
AU2018201909A1 (en) 2018-04-12
CA3159064A1 (en) 2013-08-01
US20220168263A1 (en) 2022-06-02
MX2020007448A (es) 2020-09-14
US10149829B2 (en) 2018-12-11
US20210161854A1 (en) 2021-06-03
CA3085116C (en) 2022-07-19
CN104379135B (zh) 2020-07-14
IL269054A (en) 2019-10-31
RU2631602C2 (ru) 2017-09-25
WO2013112949A3 (en) 2013-09-19
JP6267260B2 (ja) 2018-01-24
IL233714A0 (en) 2014-09-30
WO2013112951A2 (en) 2013-08-01
US20240156775A1 (en) 2024-05-16
US20130197076A1 (en) 2013-08-01
US9539234B2 (en) 2017-01-10
JP2018080181A (ja) 2018-05-24
EP2806863A2 (en) 2014-12-03
DK2806863T3 (en) 2017-10-30
EP3300728A3 (en) 2018-05-02
CA2861111C (en) 2021-11-23
US20190070144A1 (en) 2019-03-07
US20200179326A1 (en) 2020-06-11
EP2806863B1 (en) 2017-08-09
KR102317399B1 (ko) 2021-10-26
US11850229B2 (en) 2023-12-26
RU2014134555A (ru) 2016-03-20
HRP20171600T1 (hr) 2017-12-15
AU2013211878A1 (en) 2014-08-21
US11826339B2 (en) 2023-11-28
AU2013211880A1 (en) 2014-08-21
AU2019203910B2 (en) 2021-09-23
JP2021073222A (ja) 2021-05-13
CA2861108C (en) 2020-09-08
ES2897671T3 (es) 2022-03-02
US9855241B2 (en) 2018-01-02
JP7119261B2 (ja) 2022-08-17
JP2015509106A (ja) 2015-03-26
EP3300728A2 (en) 2018-04-04
AU2016204178A1 (en) 2016-07-14
US10980770B2 (en) 2021-04-20
US8785492B2 (en) 2014-07-22
CN104519877A (zh) 2015-04-15
CL2014001992A1 (es) 2015-03-13
JP2016172737A (ja) 2016-09-29
BR112014018433A8 (pt) 2017-07-11
US20210330634A1 (en) 2021-10-28
US20140296332A1 (en) 2014-10-02
US20200009106A1 (en) 2020-01-09
MX2019012197A (es) 2020-08-31
EP2806864B1 (en) 2021-08-25
IL269041A (en) 2019-10-31
US20180071245A1 (en) 2018-03-15
BR112014018429A8 (pt) 2017-07-11
JP2020097602A (ja) 2020-06-25
US20170087123A1 (en) 2017-03-30
CN110215440A (zh) 2019-09-10
US20150216837A1 (en) 2015-08-06
RU2014134552A (ru) 2016-03-20
US9549913B2 (en) 2017-01-24
US11833130B2 (en) 2023-12-05
AU2019204306A1 (en) 2019-07-04
KR20190006598A (ko) 2019-01-18
JP2022095662A (ja) 2022-06-28
EP3620794A1 (en) 2020-03-11
CO7131366A2 (es) 2014-12-01
US20210205261A1 (en) 2021-07-08
IN2014DN07050A (es) 2015-04-10
US10945988B2 (en) 2021-03-16
HUE034876T2 (hu) 2018-03-28
JP2017039731A (ja) 2017-02-23
KR20190069617A (ko) 2019-06-19
MX2014009079A (es) 2016-01-25
KR20220087582A (ko) 2022-06-24
EP2806864A2 (en) 2014-12-03
JP2023071727A (ja) 2023-05-23
KR102593047B1 (ko) 2023-10-24
KR20200022543A (ko) 2020-03-03
AU2016204217A1 (en) 2016-07-14
BR112014018429A2 (es) 2017-06-20
US20140296330A1 (en) 2014-10-02
CN104379135A (zh) 2015-02-25
AU2019203910A1 (en) 2019-06-20
CA3085116A1 (en) 2013-08-01
US20220175716A1 (en) 2022-06-09
CN111603460A (zh) 2020-09-01
KR102411809B1 (ko) 2022-06-22
RU2650647C2 (ru) 2018-04-16
IN2014DN07132A (es) 2015-04-24
ES2646197T3 (es) 2017-12-12
US9060995B2 (en) 2015-06-23
MX367184B (es) 2019-08-08
BR112014018433A2 (es) 2017-06-20
CL2014001993A1 (es) 2015-03-13
AU2018201302A1 (en) 2018-03-15
KR20210118983A (ko) 2021-10-01
KR102307012B1 (ko) 2021-09-30
KR101895653B1 (ko) 2018-09-05
KR20140116927A (ko) 2014-10-06
KR20180100450A (ko) 2018-09-10
KR20140117537A (ko) 2014-10-07
KR102171965B1 (ko) 2020-10-30
SI2806863T1 (sl) 2017-12-29
KR20200123873A (ko) 2020-10-30
US20140357710A1 (en) 2014-12-04
CO7131353A2 (es) 2014-12-01
US20140296331A1 (en) 2014-10-02
US20220168264A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
AU2016204217A1 (en) Treatment of circadian rhythm disorders
MX2019006218A (es) Tratamiento de trastornos del ritmo circadiano.
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
CL2016000354A1 (es) Modulación de la inmunidad tumoral
MX2015011296A (es) Dispositivo foto-terapeutico, metodo y uso.
ZA201807903B (en) Methods of treating circadian rhythm sleep disorders
CA2871774C (en) Use of n-acetylcysteine amide in the treatment of disease and injury
PH12015502302B1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
IL245738A0 (en) Oxindole derivatives, ways of their preparation and their therapeutic use in the treatment of ampk-related diseases
BR112014016937A2 (pt) terapia de combinação para o tratamento de desordens de audição e do equilíbrio
SMT201700098B (it) Aclidinio per l&#39;uso nel miglioramento della qualità del sonno in pazienti con malattie respiratorie
UA108975C2 (uk) Застосування співполімеру натрійкарбоксиметилцелюлози і госиполу в комплексній терапії пацієнтів з аутистичними розладами і когнітивними порушеннями
EA201591185A1 (ru) Применение пидотимода для лечения псориаза
SG10201908587PA (en) Treatment regimens
EA201591184A1 (ru) Применение пидотимода для лечения атопического дерматита
MX2015008454A (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
AR108472A1 (es) Métodos de tratamiento de los trastornos del ritmo circadiano del sueño
UA87193U (ru) Способ лечения наркотической зависимости

Legal Events

Date Code Title Description
FG Grant or registration